Recent Studies on Luliconazole Drug Exhibiting Anti-Fungal Activity

Abstract

An imidazole anti-fungal medication called luliconazole has a brand-new structure that combines the imidazole molecule with the ketone dithioacetate structure. New imidazole anti-fungal medications, lanoconazole and its sibling drug luliconazole block the enzyme lanosterol 14-demethylase. Both substances are effective anti-fungal agents against a variety of yeasts, NDMs, and dermatophytes. Lanoconazole is a racemic mixture with less potent anti-fungal properties. Luliconazole is the R-enantiomer of this compound. Luliconazole works well against dermatophytes. Skin infections are treated with luliconazole, a topical imidazole anti-fungal. It possesses anti-fungal activity against Aspergillus fumigatus, Malassezia spp., and Candida albicans, according to in vitro/in vivo investigations. Despite being an azole, liconazole has terbinafine-like fungicidal activity against Trichophyton spp. Its clinical anti-fungal efficacy may be explained by luconazole's high in vitro anti-fungal activity and favourable pharmacokinetic characteristics in skin. The imidazole anti-fungal luciconazole is being developed in the US to treat dermatophytic skin and nail infections. Luliconazole has a license from the FDA to treat tinea pedis, tinea corporis, and tinea cruris. It has been demonstrated that liconazole is more effective than anti-fungals like fluconazole, terbinafine, and itraconazole. A favourable safety profile exists for liconazole. Luliconazole is categorized as pregnancy category C because there isn't enough appropriate and well controlled research on this drug's effects on pregnant women. Whether luliconazole gets into breast milk is unknown. Therefore, it should not be eaten by women who are nursing or pregnant. This review helps the viewer to understand thoroughly about the anti-fungal activity of luliconazole.